BRPI0810495A2 - difenil-di-hidro-imidazopiridinonas - Google Patents

difenil-di-hidro-imidazopiridinonas

Info

Publication number
BRPI0810495A2
BRPI0810495A2 BRPI0810495A BRPI0810495A BRPI0810495A2 BR PI0810495 A2 BRPI0810495 A2 BR PI0810495A2 BR PI0810495 A BRPI0810495 A BR PI0810495A BR PI0810495 A BRPI0810495 A BR PI0810495A BR PI0810495 A2 BRPI0810495 A2 BR PI0810495A2
Authority
BR
Brazil
Prior art keywords
dihydroimidazopyridinones
diphenyl
diphenyl dihydroimidazopyridinones
Prior art date
Application number
BRPI0810495A
Other languages
English (en)
Inventor
Thanh Vu Binh
Romyr Dominique
Qiao Qi
Alan Goodnow Robert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0810495A2 publication Critical patent/BRPI0810495A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0810495A 2007-04-12 2008-04-02 difenil-di-hidro-imidazopiridinonas BRPI0810495A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92311007P 2007-04-12 2007-04-12
PCT/EP2008/053903 WO2008125487A1 (en) 2007-04-12 2008-04-02 Diphenyl-dihydro-imidazopyridinones

Publications (1)

Publication Number Publication Date
BRPI0810495A2 true BRPI0810495A2 (pt) 2018-10-30

Family

ID=39478351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810495A BRPI0810495A2 (pt) 2007-04-12 2008-04-02 difenil-di-hidro-imidazopiridinonas

Country Status (18)

Country Link
US (1) US7625895B2 (pt)
EP (1) EP2146986B1 (pt)
JP (1) JP2010523616A (pt)
KR (1) KR20090118116A (pt)
CN (1) CN101657449B (pt)
AR (1) AR066014A1 (pt)
AT (1) ATE514696T1 (pt)
AU (1) AU2008238062A1 (pt)
BR (1) BRPI0810495A2 (pt)
CA (1) CA2684008A1 (pt)
CL (1) CL2008001047A1 (pt)
ES (1) ES2367228T3 (pt)
IL (1) IL201021A0 (pt)
MX (1) MX2009011019A (pt)
PE (1) PE20090229A1 (pt)
RU (1) RU2009141522A (pt)
TW (1) TW200848033A (pt)
WO (1) WO2008125487A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010205201A1 (en) 2009-01-16 2011-08-04 Daiichi Sankyo Company,Limited Imidazothiazole derivative having proline ring structure
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
EP2707372B1 (en) 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
MX2021003999A (es) 2018-10-08 2021-06-23 Univ Michigan Regents Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
EP4121043A1 (en) 2020-03-19 2023-01-25 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
ATE389400T1 (de) * 2001-12-18 2008-04-15 Hoffmann La Roche Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
DE60227108D1 (de) * 2001-12-18 2008-07-24 Hoffmann La Roche Cis-imidazoline als mdm2-hemmer
MXPA05013279A (es) * 2003-06-17 2006-03-09 Hoffmann La Roche Cis-2,4,5-triaril-imidazolinas.
ES2314660T3 (es) 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag Nuevas cis-imidazolinas.
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
EP1979338A1 (en) 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53

Also Published As

Publication number Publication date
AR066014A1 (es) 2009-07-15
RU2009141522A (ru) 2011-05-20
TW200848033A (en) 2008-12-16
CA2684008A1 (en) 2008-10-23
IL201021A0 (en) 2010-05-17
JP2010523616A (ja) 2010-07-15
PE20090229A1 (es) 2009-03-27
US7625895B2 (en) 2009-12-01
KR20090118116A (ko) 2009-11-17
ES2367228T3 (es) 2011-10-31
US20080255119A1 (en) 2008-10-16
MX2009011019A (es) 2009-10-29
EP2146986A1 (en) 2010-01-27
CL2008001047A1 (es) 2009-01-16
EP2146986B1 (en) 2011-06-29
CN101657449A (zh) 2010-02-24
ATE514696T1 (de) 2011-07-15
WO2008125487A1 (en) 2008-10-23
AU2008238062A1 (en) 2008-10-23
CN101657449B (zh) 2012-06-06

Similar Documents

Publication Publication Date Title
BRPI0810495A2 (pt) difenil-di-hidro-imidazopiridinonas
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DK2514750T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
DE112008003636A5 (de) Mehrzuggruppierer
DE502007001207D1 (de) Elektrosaugkopf
BRPI0814519A2 (pt) Organopolissiloxano
DE602008000749D1 (de) Buschschneider
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
AT505058A3 (de) Türschliesssystem
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE502008003063D1 (de) Magnetventilinjektor
DE112008003196A5 (de) Handpipettiergerät
DK2219566T3 (da) Ortoseled
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
DE602008006131D1 (de) Schussfadeneintragdüse
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung
CU20090155A7 (es) Macrolidos
FI20075730A0 (fi) Reunaohjain
DE102007038931A8 (de) Fadenlagennähwirkstoffe
DE112008002909A5 (de) Verwahrbehältnis
DE502008000815D1 (de) Kraftfahrzeugsitzverstellantrieb

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.